The US Food and Drug Administration (FDA) has granted Fast Track designation to Sumitomo Pharma’s DSP-5336 for relapsed or refractory acute myeloid leukaemia (AML). The drug is intended for patients with a KMT2A rearrangement, also known as, mixed lineage leukaemia rearrangement (MLLr) or nucleophosmin mutation (NPM1m). DSP-5336 is an investigational small molecule inhibitor of the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!